Gleevec or Imatinib is the first member of a new class of agents that act by specifically inhibiting a certain enzyme that is characteristic of a particular cancer cell for CML Leukemia, rather than non-specifically inhibiting and killing all rapidly dividing cells, this is a "targeted therapy" which kills only the cancer cells. "Targeted Cancer Therapies" are the future of Oncology. My website shows these programs that will revolutionize Oncology and the Pharmaceutical Industry (the worlds largest industry). My website; http://www.biologicalcancertreatments.com/
News 
Market Data 
Discover 
